Effect of exenatide on aortic stiffness and blood pressure parameters
Yükleniyor...
Tarih
2017
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: Eksenatid ile insülin glarjinin sistolik ve diyastolik kan basıncı, nabız basıncı ve aortik sertlik parametreleri üzerine etkinliğini değerlendirmek.Gereç ve Yöntemler: Başlangıçta en az 2 ay metformin tedavisi alan, insülin ve inkretin bazlı tedaviler için naif, vücut kitle indeksi (VKİ) =25-45 kg/m2aralığında olan 34 tip 2 diyabetli hasta, glukagon like peptit-1 (GLP-1) analogu olan eksenatid ve insülin glarjin kollarına randomize edildi. 26 hafta boyunca izlendi. Aortik sertlik ölçümü transtorasik ekokardiogra? ve hemodinamik veriler kullanılarak hesaplandı.Vücut ağırlığı ve total vücut yağ kütlesi biyoimpedansla ölçüldü. Bulgular: Her iki çalışma kolunda sistolik ve diyastolik kan basıncında anlamlı değişiklik görülmedi. Aortik serlik parametrelerine etkileri değerlendirildiğinde başlangıç ve sonuç değerlerinde anlamlı farklılık tespit edilmedi. Aortik sertlik ?-indeksi ile kilo değişimi arasında negatif(r=-0.322) ve aortik distansibilite ile kilo değişimi arasında pozitif korelasyon tespit edildi (r=0.386).Tartışma: Eksenatid ve insulin glarjin çalışma periyodu boyunca kan basıncı parametrelerine nötral etki göstermiştir. Eksenatid aortik sertlik parametrelerinde değişikliğe neden olmamıştır. 26 haftalık eksenatid tedavisi glisemik regülasyon yanında, vücut ağırlığı ve yağ kütlesikaybına neden olmaktadır. Vücut ağırlığı ve yağ kütlesi kaybı aortic sertlik belirteçlerine olumlu etmektedir
Purpose: To evaluate the effects of exenatide and insulin glargine on systolic and diastolic blood pressure, pulse pressure, and aortic stiffness parameters. Materials and Methods: Thirty-four patients with type 2 diabetes who were receiving metformin treatment for at least two months but naivefor insulin and incretin based treatments, with body mass index (BMI) = 25-45 kg/m2, were randomized into exenatide a glucagon like peptide-1 (GLP–1) analog and insulin glargine arms and were followed for 26 weeks. Aortic stiffness parameters were calculated using transthoracic echocardiography and hemodynamic data. Body weight and total body fat mass were measured by bioimpedance analysis.Results: There was no signi?cant change in systolic and diastolic blood pressures in both arms. When the effects on aortic stiffness parameters were evaluated there was no signi?cant difference in the baseline and outcome values of both arms. Changes in body weight hada negative correlation with aortic stiffness ? index (r=–0.322) and a positive correlation with aortic distensibility (r=0.386). Discussion: Throughout the study period, exenatide and insulin glargine had a neutral effect on blood pressure parameters. Exenatide didnot cause any change in aortic stiffness parameters. A 26-week exenatide treatment leads to loss of body weight and fat mass along withglycemic regulation. Body weight and fat mass loss have a positive impact on aortic stiffness indicators
Purpose: To evaluate the effects of exenatide and insulin glargine on systolic and diastolic blood pressure, pulse pressure, and aortic stiffness parameters. Materials and Methods: Thirty-four patients with type 2 diabetes who were receiving metformin treatment for at least two months but naivefor insulin and incretin based treatments, with body mass index (BMI) = 25-45 kg/m2, were randomized into exenatide a glucagon like peptide-1 (GLP–1) analog and insulin glargine arms and were followed for 26 weeks. Aortic stiffness parameters were calculated using transthoracic echocardiography and hemodynamic data. Body weight and total body fat mass were measured by bioimpedance analysis.Results: There was no signi?cant change in systolic and diastolic blood pressures in both arms. When the effects on aortic stiffness parameters were evaluated there was no signi?cant difference in the baseline and outcome values of both arms. Changes in body weight hada negative correlation with aortic stiffness ? index (r=–0.322) and a positive correlation with aortic distensibility (r=0.386). Discussion: Throughout the study period, exenatide and insulin glargine had a neutral effect on blood pressure parameters. Exenatide didnot cause any change in aortic stiffness parameters. A 26-week exenatide treatment leads to loss of body weight and fat mass along withglycemic regulation. Body weight and fat mass loss have a positive impact on aortic stiffness indicators
Açıklama
Anahtar Kelimeler
Endokrinoloji ve Metabolizma
Kaynak
Turkish Journal of Endocrinology and Metabolism
WoS Q Değeri
N/A
Scopus Q Değeri
Q4
Cilt
21
Sayı
4
